Efficacy vs effectiveness in prostate-specific antigen screening

Journal of the National Cancer Institute

Volumn 102, Issue 5, 2010, Pages 288-289

  Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SCREENING; CLINICAL PRACTICE; DIGITAL RECTAL EXAMINATION; EDITORIAL; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; EUROPE; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 77749254843     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq002     Document Type: Editorial

References (3)

1. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310- 1319.
2. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-1328.
3. Wever EM, Draisma G, Heijnsdijk EAM, et al. Prostate-specifc antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst. 2010; 102(5):352-355.